InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - June 23, 2020) -  FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9), a specialty, biotech pharmaceutical R&D company, focused on developing, over time, multiple applications of its lead compound FSD201, has announced favorable topline results from its Phase I first-in-human safety and tolerability study of ultra-micronized palmitolylethanolamide or PEA. This randomized, double-blind, placebo-controlled study of PEA, or FSD201, was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia.InvestmentPitch.com has produced a \"video\" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"FSD Pharma\" in the search box.Cannot view this video? Visit:https://www.youtube.com/watch?v=HWH2r2vC8s0The trial sequentially tested 48 healthy adult men and women with single ascending doses ranging from 600 mg to 2400 mg tablets and multiple ascending doses ranging from 600 mg to 1200 mg tablets, administered twice daily for 7 consecutive days. The single ascending dose subjects also were tested for food effect.The study was led by principal researcher Jason Lickliter, MD, Chief Medical Officer of Nucleus Network, Australia's largest and most experienced Phase 1 clinical research organization. The study found ultra-micronized PEA to be safe and well tolerated. There were no abnormal laboratory findings or ECGs observed during the study and no serious adverse events were reported, although mild and self-limiting side effects were reported and were deemed unlikely to be related to study drug. No subjects withdrew due to an adverse event and all eligible subjects completed all doses. The pharmacokinetic profile of FSD201 in this study is still being analyzed. Dr. Raza Bokhari, Executive Co-Chairman and CEO, stated: \"We are delighted to be reporting favorable topline findings from our Phase 1 first-in-human safety and tolerability study with FSD201. I congratulate our pharmaceutical team, led by Dr. Edward Brennan. This study has also successfully validated the considerab...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B